Night - Clear. Winds NW at 4 to 10 mph (6.4 to 16.1 kph). The overnight low will be 35 °F (1.7 °C). Sunny with a high of 73 °F (22.8 °C). Winds variable at 4 to 6 mph (6.4 to 9.7 kph). Sunny ...

The move: Gilead Sciences dropped 2.52% in premarket trading, falling to $107.45 per share Wednesday morning. The biopharmaceutical company is up 19.34% for the year. Why: The stock's decline ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

BofA notes press reports that the Trump administration is allegedly considering cutting HIV prevention activities from the CDC budget and that ...

Investing.com -- Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human Services Department is considering major cuts to federal ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical powerhouse known for its groundbreaking HIV treatments, stands at a critical juncture as it navigates a changing landscape in the ...

Investing.com -- Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the Health and Human Services Department is considering ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Norway served as the inspiration for this kingdom, which is one of the top fictional Disney lands we'd love to visit. Between ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...